Acute Ischemic Stroke – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Acute Ischemic Stroke (AIS) occurs when a blood vessel supplying the brain becomes obstructed, resulting in a significant reduction or cessation of blood flow to the affected area. Stroke stands as one of the foremost contributors to mortality and disability across the globe. Modifiable risk factors encompass a range of health conditions and lifestyle factors that individuals have the potential to influence. These include hypertension, diabetes mellitus, cardiac disease, elevated cholesterol levels, prior stroke history, carotid artery stenosis, and hyperhomocysteinemia. The obstruction of cerebral blood flow precipitates the onset of acute ischemic stroke, where the prognosis is notably influenced by the time elapsed since symptom onset. At the cellular level, the abrupt cessation of blood flow due to a blood clot (thrombus) or plaque (fatty deposits) disrupts the delivery of essential nutrients and oxygen to brain tissue, leading to irreversible damage. Ischemic stroke triggers mitochondrial cell death, exacerbating tissue injury. Computed tomography (CT) of the brain is typically the initial imaging modality employed for stroke detection. Widely accessible in hospital settings, CT scans offer rapid results and enable the identification of intracranial hemorrhage, necessitating distinct treatment approaches from acute ischemic stroke. Brain magnetic resonance imaging (MRI) is also frequently utilized for diagnosing acute ischemic stroke. In AIS management, tissue plasminogen activator (tPA) represents the gold standard treatment associated with enhanced patient clinical outcomes. Administering intravenous tPA promptly following the onset of stroke symptoms correlates with improved prognosis, underscoring the importance of timely intervention in AIS management.

Thelansis’s “Acute Ischemic Stroke Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Ischemic Stroke treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Acute Ischemic Stroke across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Acute Ischemic Stroke Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Acute Ischemic Stroke – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Acute Ischemic Stroke, Acute Ischemic Stroke market outlook, Acute Ischemic Stroke competitive landscape, Acute Ischemic Stroke market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)